Kornimate/medical-research-clean huggingface dataset:
oral appliances for sleep apnea of the elderly

Conditions: Obstructive Sleep Apnea; Hypertension; Cardiovascular Disease

Summary: sleep apnea involves significant increases in disease and death, but its consequences in people over 65 years of age are incompletely recognized. intraoral mandibular advancement appliances reduce the number of apneas and hypopneas. the investigators hypothesized that oral appliances provided to the elderly may prevent hypertension and other consequences of sleep apnea in large populations, at a favorable cost/benefit relationship for the public health system.

sleep disorders involve significant increases in morbidity and mortality, particularly in those over 60 years. sleep apnea is the leading identifiable cause of hypertension, which is the main cause of cardiovascular disease. some degree of sleep apnea is present in up to 95% of the elderly. intraoral mandibular advancement appliances reduce the number of apneas and hypopneas. we hypothesized that reducing the number of sleep apnea events through oral appliances is effective in preventing high blood pressure and other consequences of sleep apnea in the elderly in the public health system setting. in this superiority parallel, randomized, and double-blinded study we will compare the effect of an intraoral appliance with mandibular advancement to a placebo device without mandibular advancement in preventing high blood pressure and other consequences of sleep apnea in the elderly. the duration of intervention will be of 12 months, with assessments at three, six months, and 12 months.

Eligibility criteria:
inclusion criteria: * mandibular advancement of at least 3 mm * mouth opening of at least 30 mm * sleep apnea with apnea-hypopnea index between 10 and 50 events/hour * agree to participate in the study by signing the informed consent exclusion criteria: * already in treatment for sleep apnea * self-reported severe or terminal illness * physical disability * inability to communicate verbally * dementia in the mini-mental state examination * plan to move to a different a city or to be institutionalized in the next year * participation in another clinical trial * less than eight teeth, periodontal disease, or tmj problems

Keywords: elderly obstructive sleep apnea mandibular advancement oral appliance hypertension cardiovascular disease quality of life
life style modification for breast canccer survivors using mobile app-based human coaching program

Conditions: Breast Cancer Survivors

Summary: this study is aimed to investigate whether mobile app-based human coaching program for 6 months is effective for reducing bmi in breast cancer survivors with overweight and obesity.


Eligibility criteria:
inclusion criteria: 1. breast cancer survivors who have completed acute treatment of breast cancer 2. age: 18 \~ 70 year old 3. stage: i, ii, iii 4. bmi≥25.0 kg/m2 5. breast cancer survovrs who can use mobile application program 6. breast cancer survovrs who agree with this study's consent exclusion criteria: 1. stage iv, carcinoma in situ 2. breast cancer survivors who don't use smartphone 3. breast cancer survivors with previous other malignant disease 4. breast cancer survivors with multiple malignancies 5. breast cancer survivors with uncontrolled chronic comorbid disease 6. breast cancer survovrs who disagree with this study's consent
nerve block anesthesia combined with sedative anesthesia versus general anesthesia in surgery for csdh

Conditions: Chronic Subdural Hematoma; Anesthesia

Summary: a prospective, multicenter, randomized controlled trial is designed to evaluate the safety of nerve block anesthesia combined with sedative anesthesia versus general anesthesia during burr hole craniostomy with drainage for chronic subdural hematoma.

this is a prospective, multi-centre, randomised, controlled, single-blinded, non-inferiority trial. patients with chronic subdural hematoma undergoing burr-hole drainage will be randomly allocated to receive either the cranial nerve block with dexmedetomidine sedation or general anaesthesia. patients in the cranial nerve block with dexmedetomidine sedation group will receive cranial nerve block with 0.5% ropivacaine and 1% lidocaine mixture according to incision, combined with dexmedetomidine infusion at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5 to 1ug/kg/h until the end of the operation. patients in the general anaesthesia group will be induced with propofol or etomidate, sufentanil, rocuronium or cis-atracurium and be maintained with total intravenous anaesthesia. the primary outcome is the incidence of intraoperative limb movement. secondary outcomes include postoperative delirium within five days after surgery, anaesthesia conversion, postoperative neurological function, intraoperative awareness, and recurrence rate of hematoma within 6 months after surgery.

Eligibility criteria:
inclusion criteria: * patients with chronic subdural hematoma with preoperative neurological dysfunction for burr hole drainage; * age beween 18 to 80 * chronic subdural hematoma verified on cranial computed tomography or magnetic resonance imaging with hematoma thickness \>1.0cm or midline shift \>1.0 cm. * written informed consent obtained exclusion criteria: * preoperative unconsciousness (glasgow coma scale\<13, or markwalder grade 2-4) or cognitive dysfunction (mini-cog≤3, or mmse≤20) * preoperative sensory or motor aphasia * recurrence of hematoma with previous surgery for chronic subdural hematoma. * previous intracranial surgery or with intracranial lesion * with severe comorbidity or other organ dysfunction * allergic to anesthetics * severe coagulopathy or high risk of life-threatening bleeding * participating in another research
lung screening in people cured of hodgkin lymphoma

Conditions: Hodgkin Lymphoma; Lung Cancer

Summary: a single site non-commercial study in which people treated for hodgkin lymphoma survivors will be invited to have a single low dose ct of thorax for lung cancer screening


Eligibility criteria:
inclusion criteria: * aged 18-80 * 5 year or more survivor of hl * any of: a) treated with radiotherapy for hl with radiation dose to the lung b) an alkylating agent containing chemotherapy regimen known to increase lung cancer risk * living within approximately 40 miles of the christie hospital exclusion criteria: * previous diagnoses of malignant neoplasm of trachea, bronchus, lung, thymus or pleura * a current diagnosis of metastatic cancer * residents in nursing homes or housebound * had a ct scan of the thorax within the last 12 months * pregnant women * unable to provide consent

Keywords: screening low dose ct scan
a phase iii study of ak104 as adjuvant therapy in hcc with high risk of recurrence after curative resection

Conditions: Hepatocellular Carcinoma

Summary: the efficacy and safety of ak104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.


Eligibility criteria:
inclusion criteria: 1. pathological diagnosis of hcc without any metastasis; 2. receiving radical resection as the only anti-tumor treatment; 3. no evidence of residual cancer found during or after the operation; 4. presence of any high risk factor of postoperative recurrence; 5. child-pugh grade: a; 6. ecog score: 0; 7. controlled underlying causes of hcc. exclusion criteria: 1. fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc; 2. any anti-tumor treatment other than radical surgery before randomization; 3. precarious liver function indicated by severe complications; 4. recent procedures or medications leading to high risk of bleeding; 5. poorly controlled or symptomatic hypertension, congestive heart failure, arrhythmia, etc; 6. failure of performing enhanced ct or mri scans of the liver; 7. recent severe infections or systemic antibiotics use; 8. active autoimmune diseases; 9. history of other incurable malignant tumors; 10. history of transplantation; 11. pregnancy.
liver regeneration therapy using autologous adipose tissue derived stromal cells

Conditions: Liver Cirrhosis

Summary: mesenchymal stem cells have the capability to differentiate into hepatocytes and will be useful for liver regeneration. adipose tissue is relatively enriched with mesenchymal stem cells compared to bone marrow tissue. in this trial, eligible liver cirrhosis patients will receive autologous adipose tissue derived stromal cells which include such mesenchymal stem cells.

the population of the liver cirrhosis patients is enormous in japan and the only radical treatment for them is liver transplantation. however, the number of giving donors is extremely limited. mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as hepatocytes. they reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. the latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. in this study, the cirrhotic patients will receive autologous adipose tissue derived stromal cells which contains substantial number of mesenchymal stem cells.

Eligibility criteria:
inclusion criteria: * liver cirrhosis patients * platelets count in peripheral blood: over 7.0x10\^4/microliter * serum creatinine: less than 1.5 mg/dl * capable of understanding the features of this clinical trial exclusion criteria: * associated with risky gastroesophageal varices for bleeding * severe portal hypertension * complicated with severe heart failure * renal disease * respiratory disease * hematological disease * coagulation disturbance and judged to be excluded by doctors * associated with malignancy * past history of the following: * malignancy * ischemic heart disease * cerebrovascular disease (cerebral infarction, cerebral hemorrhage) * decompensated status of liver cirrhosis * pregnant, or possibility of pregnancy * infected with hiv * under mediation with adrenal corticoid steroid, anti-histamine drug * anticipated with difficulty of follow-up observation * anticipated with inconsistency of following the protocol * addiction of alcohol drinking and unable to stop drinking * other candidates who are judged to be not applicable to this study by doctors

Keywords: liver cirrhosis
the effects of balance and respiratory muscle training on functional capacity, balance, respiratory function and respiratory muscle strength in children with cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: cerebral palsy (cp) is a permanent, non-progressive disorder in which the immature brain is affected by various causes in the prenatal, perinatal or postnatal period. damage to the central nervous system in children with cp causes motor problems, balance and postural disorders. it is reported in the literature that the effects of balance and the effects of balance exercises in children with cp, similarly respiratory effects were also investigated. balance and balance responses are especially important in children with ambulatory sp and balance problems are seen in most cp children. insufficient control of respiratory muscles affects pulmonary ventilation negatively in children with cp. however, it seems that cp has limited articles in which respiratory muscle strength is investigated, and also limited studies involving inspiratory muscle training. inspiratory muscle training is shown to improve pulmonary function and diaphragm (which is one of the core muscles) strength and have an effect on balance. studies showed that respiratory muscle strength in children with cp is lower than in children with normal development. nevertheless, there was no study showing the effects of respiratory muscle training on functional capacity and balance in children with cp. the aim of this study is to investigate the effects of balance training and inspiratory muscle training on functional capacity, balance, respiratory function and respiratory muscle strength in children with cp.


Eligibility criteria:
inclusion criteria: * cerebral palsy diagnosis * children with level i or ii according to gross motor classification system exclusion criteria: * orthopedic surgery and / or botox application in the lower extremity in the last 6 months * severe convulsions that can not be controlled by drugs * congenital malformation accompanying cerebral palsy

Keywords: cerebral palsy balance inspiratory muscle training 6-minute walk test pulmonary function test postural stability
influence of cytochrome p2b6 on efavirenz dose in hiv-infected thai patients

Conditions: Cytochrome P-450 CYP2B6; Efavirenz; HIV

Summary: genetic polymorphisms of cytochrome p450 2b6 (cyp2b6) are associated with lower rate of efv metabolism and lead to high exposure, as well as a higher risk of neuropsychiatric adverse event especially homozygous variant cyp2b6 \*6/\*6. this trial was designed to compare the proportion of patients who had undetectable hiv rna at 24 weeks after art initiation between patient who did cyp 2b6 guided efv dose and who did not.


Eligibility criteria:
inclusion criteria: * age ≥18 years old * anti-hiv positive * naïve to antiretroviral drugs * meet the criteria to start art to thai national guidelines * sign inform consent exclusion criteria: * body mass index (bmi) \>25 kg/m² * pregnant women or breastfeeding * received drugs that may have interaction with efv e.g. rifampicin, fluconazole (400-800 mg), ergot alkaloid, midazolam, triazolam, ritonavir, carbamazepine, phenytoin, phenobarbitone, st john's wort * having active opportunistic infections e.g. tuberculosis, cryptococcosis, histoplasmosis, penicillosis * hepatic dysfunction as indicated by: * transaminases \>5-10 × the upper limit of normal * alp \>5-10 × the upper limit of normal * total bilirubin \>2.5-5 × the upper limit of normal

Keywords: cyp2b6 polymorphism efavirenz thai hiv-infected patient pharmacogenomic
usefulness and feasibility of ultrasound in office laryngology procedures

Conditions: Cough; Vocal Cord Atrophy; Vocal Cord Paresis; Vocal Cord Paralysis; Dysphagia; Dysphonia

Summary: investigators will assess the usefulness of using ultrasound in office procedures for laryngology interventions. participants who qualify will be adults who are undergoing superior laryngeal nerve block, injection laryngoplasty, swallowing evaluation, voice evaluation and voice therapy.


Eligibility criteria:
inclusion criteria: * us-guided injection for neurogenic cough: 1. age over 18 years 2. recommended to undergo superior laryngeal nerve block * us-assessment of superior laryngeal nerve anatomy 1. age over 18 years 2. no cough complaints * us-assessment of injectate volume: 1. documentation of unilateral vocal fold paresis/paralysis or atrophy 2. age over 18 years 3. recommended to undergo injection laryngoplasty * us-assessment of swallow: 1. age over 18 years 2. presents with swallowing complaints * us-assessment of normal swallow: 1. age over 18 years 2. presents without swallowing complaints * us-assessment of voice: 1. age over 18 years 2. undergoing evaluation of voice problems exclusion criteria: 1. age under 18 years and over 99 years 2. open neck wound including tracheostomy
contents of circulating extracellular vesicles: biomarkers in colorectal cancer patients

Conditions: Colorectal Cancer

Summary: most cancer-related deaths are caused by distant metastases, which are tumour cells that have escaped from a primary tumour and passed into the bloodstream to colonize a new organ. in this context, communication between tumour and stromal cells is essential. indeed, tumor cells interact with cells in the tumor microenvironment and are able to modify them to their advantage. both extracellular vesicles (evs) and exosomes are heterogeneous populations of small vesicles present in the tumor microenvironment and in body fluids that have recently emerged as powerful mediators involved in this communication and their transport in fluids. tumor cells release large quantities of exosomes containing tumor markers, which can then spread to distant locations. the exosomes are of endosomal origin. they are composed of proteins, lipids, rna and dna, and they circulate in the bloodstream. they can be internalized by specific distant cells and thus deliver a functional message. it has recently been shown that tumor exosomes containing pro-metastatic factors form pre-metastatic niches, before the tumor cells actually arrive, while determining the metastatic organotropism of tumors. these properties are now opening up new avenues of research in tumor biomarkers. in recent years, several studies have highlighted different markers contained specifically in exosomes derived from cancer cells. consequently, exosomes are considered as potential reservoirs of tumor biomarkers that could be clinically useful for the non-invasive diagnosis of cancer, with the advantage of being performed by liquid biopsy. the study of microrna (mirna) is of particular interest. indeed, mirnas are small non-coding rnas (between 21 and 25 nucleotides) involved in the regulation of gene expression and which are frequently deregulated in cancer. several studies underline that the variation of free mirnas in the blood is correlated with the progression of the disease, particularly in colon cancer. however, the stability of free mirnas is controversial. therefore, exosomes represent a very advantageous means of transporting mirnas in the blood, as they are able to protect mirnas from degradation by rnaase. the hypothesis of the project is that circulating exosomes derived from tumours contain markers including specific mirnas that could be used as biomarkers of early prognosis (survival and progression), easily measured in blood samples from patients with colon cancer. but other molecules contained in exosomes could also be of interest.


Eligibility criteria:
inclusion criteria: * person included in the agaric study * person who provided consent or non-opposition to inclusion in the study * available blood sample in the agaric biobank at the biological resource centre (dijon) exclusion criteria: na
visualization of carotid atherosclerosis by 68ga-msa

Conditions: Atherosclerosis; Carotid Atherosclerosis; Noninvasive Imaging of Atherosclerosis

Summary: until now, no specific atherosclerosis-targeting agent labeled with positron emitter is not yet available. investigators developed neomannosyl human serum albumin(msa) for the terminal mannose residues of msa binding with the mannose receptors of macrophages in atherosclerosis, and investigators investigate whether 68ga-msa can be a novel agent for non-invasive molecular imaging of carotid atherosclerotic lesion in pet.


Eligibility criteria:
inclusion criteria: * •coronary artery disease patients with carotid plaques * control without carotid plaque exclusion criteria: * •pregnancy, allergy to albumin, any acute or chronic inflammatory disease, hematologic disease, liver disease, renal disease

Keywords: positron emission tomography macrophage neomannosyl human serum albumin
a study to assess adverse events and change in disease activity in adult participants receiving intravenously infused telisotuzumab adizutecan alone or with standard of care in participants with post adjuvant circulating tumor dna positive colorectal cancer and no radiographic evidence of disease

Conditions: Colorectal Cancer

Summary: colorectal cancer (crc) is the third most common type of cancer diagnosed worldwide. the purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (soc) given alone. telisotuzumab adizutecan is an investigational drug being developed for the treatment of crc. this study will be divided into two groups called treatment arms. in arm 1 participants will receive telisotuzumab adizutecan alone. in arm 2 participants will receive soc alone. approximately 140 adult participants with crc will be enrolled in the study in 45 sites worldwide. in arm 1, participants will receive intravenous (iv) doses of telisotuzumab adizutecan alone. in arm 2 participants will receive soc alone. the study will run for a duration of approximately 51 months. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at an approved institution (hospital or clinic). the effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.


Eligibility criteria:
inclusion criteria: * has histologically or cytologically confirmed adenocarcinoma of the colon or rectum. * surgical tumor material should be available and must be submitted for signatera personalized panel and assessment of c-met protein levels. * must have received at least 3 months of platinum-based doublet adjuvant chemotherapy but may not have been treated with topoisomerase inhibitors as part of adjuvant therapy. * has no radiographic evidence of disease (ned) confirmed by chest, abdominal, and pelvic computed tomography (ct) scans within 6 weeks prior to cycle 1 day 1 (c1d1) dosing. * circulating tumor deoxyribonucleic acid (ctdna) positive after the end of adjuvant therapy and begin the treatment within 6 weeks after ctdna is confirmed (reported). * for participants with rectal cancer a total of at least 3 months of perioperative and/or adjuvant platinum-based doublet must have been administered. please note that short course radiation or long-course chemoradiation does not count towards this 3-month minimum of platinum-doublet perioperative and/or adjuvant therapy. * for participants with oligometastatic disease a total of at least 3 months of perioperative and/or adjuvant platinum-based doublet therapy must have been administered. exclusion criteria: * no availability of surgical tissue sample. * history of interstitial lung disease (ild) or pneumonitis that required treatment with systemic steroids, or any evidence of active ild or pneumonitis on screening chest computed tomography (ct) scan.

Keywords: colorectal cancer telisotuzumab adizutecan abbv-400, stand of care cancer
correlates of physical activity with quality of life in college women of manipal university

Conditions: Physical Activity

Summary: to find out the relationship between physical activity and * self-esteem, * sleep quality, * anxiety \& depression, * body fat percentage, * quality of life, in college females

* after receiving approval from the institutional research committee and institutional ethical committee clearance. * advertisement of the research project will be done via the head of department of each faculty of the university * subjects will be recruited on a voluntary basis and a written informed consent will be obtained after the research idea is explained. * demographics of each participant will be obtained * each of the following questionnaires will be administered: depression, anxiety and stress scale (dass-21) rosenberg self-esteem scale quality of life enjoyment and satisfaction questionnaire - short form (q-les-q-sf) pittsburgh sleep quality index (psqi) international physical activity questionnaire-long form (ipaq)

Eligibility criteria:
inclusion criteria: * female gender * age group 18-25 * indian ethnicity exclusion criteria: * known cardio-respiratory symptoms and musculoskeletal disorders curtailing form physical activity in the last 3 months, known thyroid dysfunction, known anxiety-depression disorders, recent surgery (last 3months), polycystic ovary disease (pcod), polycystic ovary syndrome (pcos) \& pregnancy.

Keywords: pa,menatal health,qol